Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910681 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Keiko Morotomi-Yano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type II, Aclarubicin, Cell Nucleus, Topoisomerase II Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science, Center for Radiation Disaster Medical Science.
Themen: Mobilisation
Abstract (Originalsprache)
DNA topoisomerase II (TOP2) is an enzyme that resolves DNA topological problems arising in various nuclear processes, such as transcription. Aclarubicin, a member of the anthracyclines, is known to prevent the association of TOP2 with DNA, inhibiting the early step of TOP2 catalytic reactions. During our research on the subnuclear distribution of human TOP2B, we found that aclarubicin affects the mobility of TOP2B in the nucleus. FRAP analysis demonstrated that aclarubicin decreased the nuclear mobility of EGFP-tagged TOP2B in a concentration-dependent manner. Aclarubicin exerted its inhibitory effects independently of TOP2B enzymatic activities: TOP2B mutants defective for either ATPase or topoisomerase activity also exhibited reduced nuclear mobility in the presence of aclarubicin. Immunofluorescence analysis showed that aclarubicin antagonized the induction of DNA damage by etoposide. Although the prevention of the TOP2-DNA association is generally considered a primary action of aclarubicin in TOP2 inhibition, our findings highlight a previously unanticipated effect of aclarubicin on TOP2B in the cellular environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan.
- Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan.
Förderung
- Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science
- Center for Radiation Disaster Medical Science
Zitieren
APA
Morotomi-Yano, K., & Yano, K. I. (2024). Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910681
Vancouver
Morotomi-Yano K, Yano KI. Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910681
BibTeX
@article{MorotomiYano2024,
author = {Morotomi-Yano, Keiko and Yano, Ken-Ichi},
title = {Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910681}
}
EUVIMED